Dexamethasone NDC 10135-795

NDC codes

FDA NDC Directory

Product NDC (as listed)10135-795Labeler and product segments. Claims need a package NDC.

Product NDC at billing width10135-0795Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
10135-795-71	10135079571	237 mL in 1 BOTTLE, GLASS (10135-795-71)Marketed from Sep 21, 1976

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dexamethasone
Generic name (nonproprietary): dexamethasone
Active ingredients: Dexamethasone — .5 mg/5mL
Dosage form: Elixir
Route: Oral
Labeler: Marlex Pharmaceuticals, Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 084754
Marketing start: Sep 21, 1976
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 10135-795_59cae836-8f84-4276-9289-73ae101b8ddfSPL ID 59cae836-8f84-4276-9289-73ae101b8ddfSPL set ID 7b51ffce-ec64-4b49-8870-b9666537c541RxCUI 309686UNII 7S5I7G3JQL
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N410135079571 followed by a unit qualifier and the quantity

Package 10135-0795-71. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 22, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Atopic dermatitis, Bronchial asthma, Contact dermatitis, Drug hypersensitivity reactions, Seasonal or perennial allergic rhinitis, and Serum sickness. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, and Acute rheumatic carditis. Dermatologic Diseases Bullous dermatitis herpetiformis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe erythema multiforme (Stevens-Johnson syndrome), Severe psoriasis, and Severe seborrheic dermatitis. Edematous States To induce a di…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 084754

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 084754
Product	Strength	Form · route	Labeler	Product NDC
Dexamethasone	Dexamethasone .5 mg/5mL	ElixirOral	ANI Pharmaceuticals, Inc.	70954-872
Dexamethasone	Dexamethasone .5 mg/5mL	ElixirOral	Bryant Ranch Prepack	72162-2600
Dexamethasone	Dexamethasone .5 mg/5mL	ElixirOral	Kesin Pharma Corporation	81033-010
Dexamethasone	Dexamethasone .5 mg/5mL	ElixirOral	Kanchan Healthcare Inc	85742-004